Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 806-984-5 | CAS number: 1392411-89-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Key value for chemical safety assessment
Effects on fertility
Link to relevant study records
- Endpoint:
- screening for reproductive / developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From September 26, 2016 to January 02, 2017
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Reason / purpose for cross-reference:
- reference to same study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 422 (Combined Repeated Dose Toxicity Study with the Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- The study integrity was not adversely affected by the deviations.
- Qualifier:
- according to guideline
- Guideline:
- other: OPPTS 870.3650, Combined Repeated Dose Toxicity Study with the Reproduction/Developmental Toxicity Screening Test
- Deviations:
- yes
- Remarks:
- The study integrity was not adversely affected by the deviations.
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 421 (Reproduction / Developmental Toxicity Screening Test)
- Deviations:
- yes
- Remarks:
- The study integrity was not adversely affected by the deviations.
- Qualifier:
- according to guideline
- Guideline:
- other: OPPTS 870.3550, Reproduction/Developmental Toxicity Screening Test
- Deviations:
- yes
- Remarks:
- The study integrity was not adversely affected by the deviations.
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
- Specific details on test material used for the study:
- Batch: DR0004393; Purity/Composition: UVCB; Appearance: Clear to slightly yellow viscous liquid
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Crl:WI(Han)
- Details on species / strain selection:
- Test system Rat: Crl:WI(Han) (outbred, SPF-Quality). Nulliparous and nonpregnant females and untreated animals were used at initiation of the study
Source: P0 Charles River Deutschland, Sulzfeld, Germany
Rationale: This species and strain of rat has been recognized as appropriate for general and reproduction toxicity studies Charles River Den Bosch has general and reproduction/developmental historical data in this species from the same strain and source. This animal model has been proven to be susceptible to the effect of reproductive toxicants - Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age: at start P0-treatment Approximately 10-12 weeks;
Number of P0-animals: 40 females and 40 males;
Acclimatization P0: At least 5 d prior to start of treatment;
Health inspection P0: At least upon receipt of the animals;
Randomization P0: Before initiation of treatment, by computer-generated random algorithm according to body weight, with all animals within ± 20% of the sex mean;
Identification P0: Earmark and tattoo.
Environmental controls for the animal room were set to maintain 18 to 24°C, a relative humidity of 40 to 70%, at least 10 room air changes/hour, and a 12 h light/12 h dark cycle. The light/dark cycle was interrupted for study related activities.
General: Sterilized sawdust as bedding material and paper as cage-enrichment/nesting material were supplied. During locomotor activity monitoring, animals were housed individually in a Hi-temp polycarbonate cage without cage-enrichment, bedding material, food and water.
Diet: Free access to pelleted rodent diet (SM R/M-Z from SSNIFF® Spezialdiäten GmbH, Soest, Germany). During motor activity measurements, animals did not have access to food for a maximum of approximately 2.5 h. There has been provided a free access to tap-water. During motor activity measurements, animals did not have access to water for a maximum of approximately 2.5 h.
Pre-mating: Animals were housed in groups of 5 animals of the same sex in Macrolon plastic cages (MIV type, height 18 cm). Post-mating: same type of cage used, males and females kept separetely. Mating: same type of cage used, animals kept in one-to-one-basis.
Lactation: Females were housed in Macrolon plastic cages (MIII type, height 18 cm). Pups were housed with the dam, except during locomotor activity monitoring of the dams when the pups were kept warm in their home cage using bottles filled with warm water. In order to avoid hypothermia of pups, pups were not left without their dam or a bottle filled with warm water for longer than 30-40 min. - Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- Oral gavage, using a plastic feeding tube. Formulations were placed on a magnetic stirrer during dosing. A dose control system (DCS) was used as additional check to verify the dosing procedure according to Standard Operating Procedures.
- Details on mating procedure:
- Following a minimum of 14 d of exposure for the males and females, one female was cohabitated with one male of the same treatment group, avoiding sibling mating. Detection of mating was confirmed by evidence of sperm in the vaginal lavage or by the appearance of an intravaginal copulatory plug. This day was designated Day 0 post-coitum. Once mating was confirmed, the males and females were separated. A maximum of 14 d was allowed for mating, after which females who had not shown evidence of mating were separated from their males. Detection of mating was not confirmed in first instance for four animals which delivered live offspring. The mating date of these animals was determined by rechecking of the vaginal lavages. This day was designated Day 0 post-coitum. Detection of mating was not confirmed for one animal which delivered live offspring. The mating date of this animal was estimated at 21 d prior to the actual delivery date. This day was designated Day 0 post-coitum.
- Analytical verification of doses or concentrations:
- yes
- Remarks:
- LC-MS/MS
- Details on analytical verification of doses or concentrations:
- No test substance was detected in the control group formulation. The concentrations analyzed in the formulations of groups 2, 3 and 4 (dosages to each group respectively: 100, 300, 1000 mg/kg bw) were in agreement with the target concentrations (i.e. mean accuracies between 90% and 110%). The formulations of Group 2 and Group 4 prepared were homogeneous (i.e. coefficient of variation ≤ 10%).
Formulations at the entire range were stable when stored at room temperature protected from light for at least 5 h (i.e. relative difference ≤ 10%).
The test substance was stable in propylene glycol over a storage period of at least 86 d at a temperature ≤ -70°C.
A dose control system (DCS) was used as additional check to verify the dosing procedure according to Standard Operating Procedures. - Duration of treatment / exposure:
- - Males were dosed for 29 d, i.e. 2 weeks prior to mating, during mating, and up to the day prior to scheduled necropsy.
- Females that delivered were exposed for 40-45 d (most females) or 53 d (one female), i.e. during 2 weeks prior to mating (with the objective of covering at least two complete estrous cycles), the variable time to conception, the duration of the pregnancy and at least 4 d after delivery up to and including the day before scheduled necropsy. Females which failed to deliver healthy offspring were exposed for 40 or 42 d. Routinely, females that are littering are left undisturbed. - Frequency of treatment:
- Once daily for 7 d per week, approximately the same time each day with a maximum of 6 h difference between the earliest and latest dose.
- Details on study schedule:
- Experimental starting date: 26 September 2016 (Randomization Dose Range Finder);
Start treatment: 10 November 2016;
Start mating: 24 November 2016;
Blood sampling: 9 December 2016 (selected males);
21 - 24 December 2016 (selected females);
Delivery of litters: (PND 1) 17 – 20 and 28 December 2016;
Necropsy: 09 December 2016 (males), 20 - 25 December 2016 and 02 January 2017 (females and pups);
Experimental completion date: 02 January 2017 (end of in-life phase). - Dose / conc.:
- 0 mg/kg bw/day (actual dose received)
- Remarks:
- Group 1
- Dose / conc.:
- 100 mg/kg bw/day (actual dose received)
- Remarks:
- Group 2
- Dose / conc.:
- 300 mg/kg bw/day (actual dose received)
- Remarks:
- Group 3
- Dose / conc.:
- 1 000 mg/kg bw/day (actual dose received)
- Remarks:
- Group 4
- No. of animals per sex per dose:
- 10
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- The test substance, formulated in propylene glycol, was administered daily by oral gavage to SPF-bred Wistar Han rats. One control group and three treated groups (100 mg/kg bw/day, 300 mg/kg bw/day, 1000 mg/kg bw/day of the test substance were tested, each consisting of 10 males and 10 females.
- Positive control:
- no positive control
- Parental animals: Observations and examinations:
- General systemic data: mortality, clinical signs, body weight, food consumption, water consumption, functional observations (hearing ability, pupillary reflex, and static righting reflex, fore- and hind-limb grip strength, locomotor activity). For details on systemic effects, please refer to section RDT: oral.
General reproduction data: Male number paired with, mating date, confirmation of pregnancy, and delivery day were recorded. Pregnant females were examined to detect signs of difficult or prolonged parturition, and cage debris of pregnant females were examined for evidence of premature delivery. Any deficiencies in maternal care (such as inadequate construction or cleaning of the nest, pups left scattered and cold, physical abuse of pups or apparently inadequate lactation or feeding) were examined. - Oestrous cyclicity (parental animals):
- Not examined
- Sperm parameters (parental animals):
- Slides of the testes of the selected 5 males of Groups 1 and 4 and of all males that failed to sire twere examined for the staging of spermatogenesis.
- Litter observations:
- Each litter was examined to determine the following, if practically possible:
Mortality / Viability;
Clinical signs: at least once daily for all animals;
Body weights: live pups were weighed on PND 1 and 4.
Sex: determined for all pups on PND 1 and 4. Sex ratio (% male pups / % female pups) was calculated per group. - Postmortem examinations (parental animals):
- Necropsy: Selected 5 animals/sex/group - Males Following completion of the mating period, females which delivered, females which failed to deliver and females with evidence of mating.
Pathology examinations:
The numbers of corpora lutea and former implantation sites were recorded for all paired females. Samples of the following tissues and organs were collected and fixed in 10% buffered formalin for further histophatological examinations: ovaries, adrenal glands, pancreas, aorta, peyer's patches, brain (cerebellum, mid-brain, cortex), pituitary gland, caecum, preputial gland, cervix, prostate gland, clitoral gland rectum, colon, salivary glands (mandibular, sublingual), coagulation gland sciatic nerve, duodenum seminal vesicles, epididymide skeletal muscle, eyes, skin, female mammary gland area, spinal cord (cervical, midthoracic, lumbar), femur including joint, spleen, heart, sternum with bone marrow, ileum, stomach, jejunum, testes, epididymides, kidneys, thymus, lacrimal gland, exorbital, thyroid including parathyroid, larynx, tongue, liver,trachea, lung, urinary bladder.
Terminal body weights were recorded from all males and the selected 5 females/group. The following organ weights were recorded from the following animals on the scheduled day of necropsy: adrenal glands, brain, epididymides, heart, kidneys, liver, ovaries, prostate, seminal vesicles including coagulating glands, spleen, testes, thymus, thyroid (including parathyroid), uterus (including cervix).
For all remaining animals: epididymides, testes examined.
Histophatology examinations:
The following slides were examined:
• The preserved organs and tissues of the selected 5 animals/sex of Groups 1 and 4
• Additional slides of the testes of the selected 5 males of Groups 1 and 4 and all males that failed to sire were examined for the staging of spermatogenesis.
• All gross lesions of all animals (all dose groups).
• The reproductive organs of all males that failed to sire and all females that failed to deliver healthy pups. - Postmortem examinations (offspring):
- Pups surviving to planned termination were killed by decapitation on Days 5 or 6 of lactation. All pups were sexed and descriptions of all external abnormalities were recorded. The stomach of pups not surviving to the scheduled necropsy date was examined for the presence of milk, if possible. If possible, defects or cause of death were evaluated.
- Statistics:
- - If the variables could be assumed to follow a normal distribution, the Dunnett-test based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel-test was applied if the data could not be assumed to follow a normal distribution.
- The Fisher Exact-test was applied to frequency data.
- The Kruskal-Wallis non-parametric ANOVA test was applied to motor activity data to determine intergroup differences. - Reproductive indices:
- For each group, the following calculations were performed:
Mating index (%)
Fertility index (%)
Conception index (%)
Gestation index (%)
Duration of gestation - Offspring viability indices:
- Percentage live males at First Litter Check
Percentage live females at First Litter Check
Viability index (%) - Clinical signs:
- no effects observed
- Dermal irritation (if dermal study):
- not examined
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- no effects observed
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Histopathological findings: non-neoplastic:
- no effects observed
- Description (incidence and severity):
- There were no morphological findings in the reproductive organs of either sex which could be attributed to the test substance.
- Histopathological findings: neoplastic:
- no effects observed
- Other effects:
- not examined
- Reproductive function: oestrous cycle:
- not examined
- Reproductive function: sperm measures:
- no effects observed
- Description (incidence and severity):
- The spermatogenic staging profiles were normal for all males examined.
- Reproductive performance:
- effects observed, non-treatment-related
- Description (incidence and severity):
- - Precoital time was not affected by treatment.
- Fertility and conception index were not affected by treatment. One female of the control group, one female dosed at 100 mg/kg bw/day and one female dosed at 300 mg/kg bw/day were not pregnant. These incidental non-pregnancies, which occurred in absence of related histopathology changes in reproductive organs or a dose-related trend, were considered to be unrelated to treatment.
- Gestation index and duration of gestation were not affected by treatment.
- Numbers of corpora lutea and implantation sites were not affected by treatment. For one female (100 mg/kg bw/day) the number of pups was slightly higher than the number of corpora lutea and implantation sites. This was considered to be due to normal resorption of these areas as these enumerations were performed on Day 5 of lactation.
- There were no morphological findings in the reproductive organs of either sex which could be attributed to the test substance.
- No signs of difficult or prolonged parturition were noted among the pregnant females. Examination of cage debris of pregnant females revealed no signs of abortion or premature birth. No deficiencies in maternal care were observed. - Key result
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- > 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment-related systemic adverse effects
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- reproduction
- Effect level:
- > 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment-related adverse effects on reproduction
- Key result
- Critical effects observed:
- no
- Clinical signs:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No clinical signs occurred among pups that were considered to be related to treatment. The clinical signs observed remained within the range considered normal for pups of this age and showed no dose-related trend. They were therefore considered to be unrelated to treatment.
- Dermal irritation (if dermal study):
- not examined
- Mortality / viability:
- mortality observed, non-treatment-related
- Description (incidence and severity):
- - At first litter check, one pup of the control goup and one pup at 1000 mg/kg bw/day were found dead. This incidental pup mortality was unrelated to treatment with the test substance. The number of living pups at first litter check was unaffected by treatment.
Viability index (number of offspring surviving until planned necropsy as percentage of number of live offspring on PND 1) was not affected by treatment. The viability indices across the groups were 95-100%.
- During lactation (mostly on PND 2), two pups of the control group, two pups at 100 mg/kg bw/day, and four pups at 300 mg/kg bw/day went missing. These missing pups were most likely cannibalized. No toxicological relevance was attributed to this post-natal mortality since the incidence of missing pups showed no dose-related trend and remained within the range considered normal for pups of this age. - Body weight and weight changes:
- no effects observed
- Description (incidence and severity):
- No toxicologically relevant changes were noted in body weights of pups. Compared to controls, male and female pups at 1000 mg/kg bw/day appeared to have slightly higher body weights at PND 1 and 4 with slightly higher body weight gain between PND 1-4. The differences were not statistically significant and remained in the normal range for pups of this age. Therefore, this finding was considered not to be toxicologically relevant.
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Sexual maturation:
- no effects observed
- Description (incidence and severity):
- Sex ratio was not affected by treatment.
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No macroscopic findings were observed among pups that were considered to be related to treatment. The nature and incidence of the few findings observed remained within the range considered normal for pups of this age, and were therefore considered to be unrelated to treatment.
- Histopathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- No macroscopic findings were observed among pups that were considered to be related to treatment.
- Other effects:
- not examined
- Behaviour (functional findings):
- not examined
- Developmental immunotoxicity:
- not examined
- Key result
- Dose descriptor:
- NOAEL
- Generation:
- F1
- Effect level:
- > 1 000 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: no treatment-related adverse effects
- Key result
- Critical effects observed:
- no
- Key result
- Reproductive effects observed:
- no
- Conclusions:
- Under the study conditions, the oral NOAEL of the substance for reproductive/developmental toxicity in rats was determined to be 1000 mg/kg bw/day.
- Executive summary:
A study was conducted to determine the toxicity of the substance on reproduction/development of rats according to OECD Guideline 422, OECD Guideline 421, OPPTS Guideline 870.3650 and OPPTS Guideline 870.3550, in compliance with GLP. The study focused on gonadal observations and reproduction/developmental effects. The details on systemic effects are summarised in repeated dose toxicity (oral) section 7.5.3. of IUCLID dataset. The test substance, formulated in propylene glycol, was administered daily by oral gavage to SPF-bred Wistar Han rats. One control group and three treated groups (0, 100, 300 and 1000 mg/kg bw/day) of the test substance were tested, each consisting of 10 males and 10 females. Males were treated for 29 d, i.e. 2 weeks prior to mating, during mating, and until scheduled necropsy. Females were treated for 40 -45 d, i.e. during 2 weeks prior to mating, during mating, during post-coitum, and at least 4 d of lactation. For parental generation, the following reproduction parameters were examined: mating, fertility and conception indices, precoital time, numbers of corpora lutea and implantation sites, gestation index and duration, parturition, and maternal care. The offspring was evaluated during early lactation period for mortality, clinical signs, body weights, and gross pathology. The sex ratio was also recorded. No treatment-related changes were observed in any of the systemic, reproductive or developmental parameters investigated, either in parents or pups. Indeed, precoital time, fertility, conception index, gestation index and duration, numbers of corpora lutea and implantation sites were not affected by treatment. Moreover there were no morphological findings in the reproductive organs of either sex which could be attributed to the test substance. The test substance did not induce any effects in the early development of the pups. Under the study conditions, the oral NOAEL of the substance for reproductive/developmental toxicity in rats was determined to be 1000 mg/kg bw/day (de Raaf - Beekhuijzen, 2017).
Reference
Effect on fertility: via oral route
- Endpoint conclusion:
- no adverse effect observed
- Dose descriptor:
- NOAEL
- 1 000 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Effect on fertility: via inhalation route
- Endpoint conclusion:
- no study available
Effect on fertility: via dermal route
- Endpoint conclusion:
- no study available
Additional information
Oral route:
A study was conducted to determine the toxicity of the test substance on reproduction/development of rats according to OECD Guideline 422, OECD Guideline 421, OPPTS Guideline 870.3650 and OPPTS Guideline 870.3550, in compliance with GLP. The study focused on gonadal observations and reproduction/developmental effects. The details on systemic effects are summarised in repeated dose toxicity (oral) section 7.5.3. of the IUCLID dataset. The test substance, formulated in propylene glycol, was administered daily by oral gavage to SPF-bred Wistar Han rats. One control group and three treated groups (0, 100, 300 and 1000 mg/kg bw/day) of the test substance were tested, each consisting of 10 males and 10 females. Males were treated for 29 d, i.e. 2 weeks prior to mating, during mating, and until scheduled necropsy. Females were treated for 40 -45 d, i.e. 2 weeks prior to mating, during mating, during post-coitum, and at least 4 d of lactation. For parental generation, the following reproduction parameters were examined: mating, fertility and conception indices, precoital time, numbers of corpora lutea and implantation sites, gestation index and duration, parturition, and maternal care. The offspring was evaluated during early lactation period for mortality, clinical signs, body weights, and gross pathology. The sex ratio was also recorded. No treatment-related changes were observed in any of the systemic, reproductive or developmental parameters investigated, either in parents or pups. Indeed, precoital time, fertility, conception index, gestation index and duration, numbers of corpora lutea and implantation sites were not affected by treatment. Moreover there were no morphological findings in the reproductive organs of either sex which could be attributed to the test substance. The test substance did not induce any effects in the early development of the pups. Under the study conditions, the oral NOAEL of the substance for reproductive/developmental toxicity in rats was determined to be 1000 mg/kg bw/day (de Raaf - Beekhuijzen, 2017).
Effects on developmental toxicity
Effect on developmental toxicity: via oral route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via inhalation route
- Endpoint conclusion:
- no study available
Effect on developmental toxicity: via dermal route
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.